[目的]探讨雄激素受体(androgen receptor,AR)在人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2)过表达型乳腺癌中的临床意义。[方法 ]用免疫组化方法检测有完整临床及随访资料的102例Her-2过表达型乳腺癌中AR表达,并分析其与临床病理特征及5年无疾病进展时间(diseasefree survinal,DFS)的相关性。[结果 ]AR在Her-2过表达型乳腺癌阳性率为75.5%(77/102);淋巴结阴性组AR表达率为84.91%(45/53),明显高于淋巴结阳性组的65.31%(32/49)(χ~2=5.286,P=0.021);Ki-67阴性组AR表达率(89.47%,34/38)明显高于Ki-67阳性组的67.19%(43/64)(χ~2=6.400,P=0.011)。生存分析显示,AR阳性组5年无瘤生存率为71.7%,明显低于AR阴性组的89.8%(χ~2=5.736,P=0.017)。Cox回归分析显示,AR是影响Her-2过表达型乳腺癌5年DFS的独立预后因素(RR=3.961,95%CI:1.008~15.574)。[结论]AR在Her-2过表达型乳腺癌中的表达率高,AR阳性患者预后较差,AR可能成为Her-2过表达型乳腺癌新的治疗靶点。 [Objective] To investigate the clinical significance of androgen receptor (AR) in human epidermal growth factor receptor-2 (Her-2) overexpression breast cancer. [Method] The expression of AR in 102 cases of Her-2 overexpression breast cancer with complete clinical and follow-up data was detected by immunohistochemistry and compared with the clinicopathological features and 5-year disease free survival (DFS) Relevance. [Results] The positive rate of AR in Her-2 overexpression breast cancer was 75.5% (77/102). The AR expression rate in lymph node-negative group was 84.91% (45/53), which was significantly higher than that in lymph node positive group (65.31%, 32 / 49) (χ ~ 2 = 5.286, P = 0.021); The Ki-67 negative group AR expression rate (89.47%, 34/38) was significantly higher than 67.6% (43/64) 2 = 6.400, P = 0.011). Survival analysis showed that 5-year disease-free survival rate was 71.7% in AR-positive group, which was significantly lower than 89.8% in AR-negative group (χ ~ 2 = 5.736, P = 0.017). Cox regression analysis showed that AR was an independent prognostic factor affecting 5-year DFS of Her-2 overexpressing breast cancer (RR = 3.961, 95% CI: 1.008 to 15.574). [Conclusion] The expression of AR in Her-2 overexpression breast cancer is high, and the prognosis of AR positive patients is poor. AR may be a new therapeutic target for Her-2 overexpression breast cancer.